Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is making significant strides in its drug development and commercialization efforts with key deals in place with major healthcare providers, including a major National Coverage Agreement with UnitedHealthcare for coverage of CNSide and deals with Humana and Highmark. Additionally, they have made solid progress in their clinical trials and the launch of CNSide in 2026 is expected to be a major positive for the company's stock. The potential cost savings associated with CNSide for late-stage LM care also present a favorable outlook for the company's future. However, there are risks to attainment of the share price target, including potential failure of product candidates in clinical trials and regulatory approval.

Bears say

Plus Therapeutics is a clinical-stage pharmaceutical company with a negative outlook based on its risky balance sheet and the potential for future reverse splits, as well as the company's focus on clinical trials and commercial scale-up for their lead drug, REYOBIQ, which is currently being evaluated in a Phase 2 trial. Additionally, Plus Therapeutics has a high operating and net loss, which may be exacerbated by risks such as Clinical/Regulatory, Partnership and Financial, Commercial, Legal and Intellectual Property, and Market Share. While the company has received positive FDA feedback and has upcoming milestones, it may be prudent to take a wait-and-see approach until the stock and management demonstrate better execution.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.